COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04024813
Recruitment Status : Suspended (unexpected histological findings in a phase 2 study in NASH patients CB8025-21730)
First Posted : July 18, 2019
Last Update Posted : December 11, 2019
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2021